Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: Consult-transplant versus consult- no-transplant analysis

Michelle L. Poon; Patricia S. Fox; Barry I. Samuels; Susan O'Brien; Elias Jabbour; Yvonne Hsu; Alison Gulbis; Martin Korbling; Richard Champlin; Lynne V. Abruzzo; Roland L. Bassett; Issa F. Khouri

doi:10.3109/10428194.2014.930848

Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: Consult-transplant versus consult- no-transplant analysis

Michelle L. Poon, Patricia S. Fox, Barry I. Samuels, Susan O'Brien, Elias Jabbour, Yvonne Hsu, Alison Gulbis, Martin Korbling, Richard Champlin, Lynne V. Abruzzo, Roland L. Bassett, Issa F. Khouri

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Allogeneic stem cell transplant (alloSCT) can overcome the adverse prognosis of chronic lymphocytic leukemia with 17p deletion (17p- CLL). However, its applicability remains unclear. Since 2007, our leukemia service has referred patients with 17p- CLL for alloSCT at presentation. In this study, the outcomes of these patients were reviewed retrospectively to determine whether they underwent alloSCT and why patients did not undergo alloSCT. Fifty-two patients with 17p- CLL who were referred to the transplant service from 2007 to 2010 were identified. Of these patients, 32 (62%) did not undergo alloSCT, mainly because of treatment- or disease-related complications (n = 15). The 2-year post-referral overall survival rates of the alloSCT and non-SCT groups were 64% and 25%, respectively (p = 0.001). These findings suggest that while alloSCT is an effective therapy in patients with 17p- CLL, pre-SCT complications may preclude a significant proportion of patients from undergoing the procedure.

Original language	English (US)
Pages (from-to)	711-715
Number of pages	5
Journal	Leukemia and Lymphoma
Volume	56
Issue number	3
DOIs	https://doi.org/10.3109/10428194.2014.930848
State	Published - Mar 1 2015

Keywords

17p-
CLL
allogeneic transplant

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

MD Anderson CCSG core facilities

Biostatistics Resource Group

Access to Document

10.3109/10428194.2014.930848

Cite this

Poon, M. L., Fox, P. S., Samuels, B. I., O'Brien, S., Jabbour, E., Hsu, Y., Gulbis, A., Korbling, M., Champlin, R., Abruzzo, L. V., Bassett, R. L., & Khouri, I. F. (2015). Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: Consult-transplant versus consult- no-transplant analysis. Leukemia and Lymphoma, 56(3), 711-715. https://doi.org/10.3109/10428194.2014.930848

Poon, ML, Fox, PS, Samuels, BI, O'Brien, S, Jabbour, E, Hsu, Y, Gulbis, A, Korbling, M, Champlin, R, Abruzzo, LV, Bassett, RL & Khouri, IF 2015, 'Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: Consult-transplant versus consult- no-transplant analysis', Leukemia and Lymphoma, vol. 56, no. 3, pp. 711-715. https://doi.org/10.3109/10428194.2014.930848

@article{1a854683b22344df8b41e0762ac23b27,

title = "Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: Consult-transplant versus consult- no-transplant analysis",

abstract = "Allogeneic stem cell transplant (alloSCT) can overcome the adverse prognosis of chronic lymphocytic leukemia with 17p deletion (17p- CLL). However, its applicability remains unclear. Since 2007, our leukemia service has referred patients with 17p- CLL for alloSCT at presentation. In this study, the outcomes of these patients were reviewed retrospectively to determine whether they underwent alloSCT and why patients did not undergo alloSCT. Fifty-two patients with 17p- CLL who were referred to the transplant service from 2007 to 2010 were identified. Of these patients, 32 (62%) did not undergo alloSCT, mainly because of treatment- or disease-related complications (n = 15). The 2-year post-referral overall survival rates of the alloSCT and non-SCT groups were 64% and 25%, respectively (p = 0.001). These findings suggest that while alloSCT is an effective therapy in patients with 17p- CLL, pre-SCT complications may preclude a significant proportion of patients from undergoing the procedure.",

keywords = "17p-, CLL, allogeneic transplant",

author = "Poon, {Michelle L.} and Fox, {Patricia S.} and Samuels, {Barry I.} and Susan O'Brien and Elias Jabbour and Yvonne Hsu and Alison Gulbis and Martin Korbling and Richard Champlin and Abruzzo, {Lynne V.} and Bassett, {Roland L.} and Khouri, {Issa F.}",

note = "Publisher Copyright: {\textcopyright} 2014 Informa UK, Ltd.",

year = "2015",

month = mar,

day = "1",

doi = "10.3109/10428194.2014.930848",

language = "English (US)",

volume = "56",

pages = "711--715",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion

T2 - Consult-transplant versus consult- no-transplant analysis

AU - Poon, Michelle L.

AU - Fox, Patricia S.

AU - Samuels, Barry I.

AU - O'Brien, Susan

AU - Jabbour, Elias

AU - Hsu, Yvonne

AU - Gulbis, Alison

AU - Korbling, Martin

AU - Champlin, Richard

AU - Abruzzo, Lynne V.

AU - Bassett, Roland L.

AU - Khouri, Issa F.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Allogeneic stem cell transplant (alloSCT) can overcome the adverse prognosis of chronic lymphocytic leukemia with 17p deletion (17p- CLL). However, its applicability remains unclear. Since 2007, our leukemia service has referred patients with 17p- CLL for alloSCT at presentation. In this study, the outcomes of these patients were reviewed retrospectively to determine whether they underwent alloSCT and why patients did not undergo alloSCT. Fifty-two patients with 17p- CLL who were referred to the transplant service from 2007 to 2010 were identified. Of these patients, 32 (62%) did not undergo alloSCT, mainly because of treatment- or disease-related complications (n = 15). The 2-year post-referral overall survival rates of the alloSCT and non-SCT groups were 64% and 25%, respectively (p = 0.001). These findings suggest that while alloSCT is an effective therapy in patients with 17p- CLL, pre-SCT complications may preclude a significant proportion of patients from undergoing the procedure.

AB - Allogeneic stem cell transplant (alloSCT) can overcome the adverse prognosis of chronic lymphocytic leukemia with 17p deletion (17p- CLL). However, its applicability remains unclear. Since 2007, our leukemia service has referred patients with 17p- CLL for alloSCT at presentation. In this study, the outcomes of these patients were reviewed retrospectively to determine whether they underwent alloSCT and why patients did not undergo alloSCT. Fifty-two patients with 17p- CLL who were referred to the transplant service from 2007 to 2010 were identified. Of these patients, 32 (62%) did not undergo alloSCT, mainly because of treatment- or disease-related complications (n = 15). The 2-year post-referral overall survival rates of the alloSCT and non-SCT groups were 64% and 25%, respectively (p = 0.001). These findings suggest that while alloSCT is an effective therapy in patients with 17p- CLL, pre-SCT complications may preclude a significant proportion of patients from undergoing the procedure.

KW - 17p-

KW - CLL

KW - allogeneic transplant

UR - http://www.scopus.com/inward/record.url?scp=84924737291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924737291&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.930848

DO - 10.3109/10428194.2014.930848

M3 - Article

C2 - 24913509

AN - SCOPUS:84924737291

SN - 1042-8194

VL - 56

SP - 711

EP - 715

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 3

ER -

Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: Consult-transplant versus consult- no-transplant analysis

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this